J Hypertens:中心血压与UAE相关性不优于周围血压

2012-11-16 高晓方译 医学论坛网

  西班牙学者的一项研究表明,尽管中心血压(cBP)与尿蛋白排泄率(UAE)相关,但其相关性不优于诊室血压。论文于2012年11月7日在线发表于《高血压杂志》(J Hypertens)。   此项研究共纳入324例伴有胰岛素抵抗的高血压患者;受试者年龄为(65±10)岁,男性为61%,糖尿病患者为77%,非糖尿病代谢综合征患者为23%。测定诊室周围血压(pBP),并通过三次晨尿样本计算

  西班牙学者的一项研究表明,尽管中心血压(cBP)与尿蛋白排泄率(UAE)相关,但其相关性不优于诊室血压。论文于2012年11月7日在线发表于《高血压杂志》(J Hypertens)。

  此项研究共纳入324例伴有胰岛素抵抗的高血压患者;受试者年龄为(65±10)岁,男性为61%,糖尿病患者为77%,非糖尿病代谢综合征患者为23%。测定诊室周围血压(pBP),并通过三次晨尿样本计算UAE平均值。对伴或不伴微量蛋白尿患者的差异,以及UAE与pBP和cBP的相关性加以分析。利用非劣性检测对上述相关性的强度进行对比。

  结果显示,25%的患者检测出微量蛋白尿。对年龄和性别进行校正后,微量蛋白尿组的中心和周围收缩压以及脉压均高于非微量蛋白尿组(P<0.05)。对于中心收缩压、周围收缩压、中心脉压和周围脉压而言,血压和UAE之间的部分偏相关系数分别为0.175、0.143、0.124和0.092。就与UAE或微量蛋白尿的相关性而言,cBP和pBP彼此间均不占优势。伴或不伴微量蛋白尿患者在cBP和pBP偏相关系数大小或均值方面均无差异。

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1837104, encodeId=8c08183e1048e, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Feb 25 01:07:00 CST 2013, time=2013-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725461, encodeId=69201e2546126, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Oct 30 23:07:00 CST 2013, time=2013-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038450, encodeId=2e9c203845040, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Jun 14 04:07:00 CST 2013, time=2013-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655616, encodeId=a944165561622, content=<a href='/topic/show?id=93e12218000' target=_blank style='color:#2F92EE;'>#中心血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22180, encryptionId=93e12218000, topicName=中心血压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d7724759256, createdName=Homburg, createdTime=Thu Dec 13 20:07:00 CST 2012, time=2012-12-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1837104, encodeId=8c08183e1048e, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Feb 25 01:07:00 CST 2013, time=2013-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725461, encodeId=69201e2546126, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Oct 30 23:07:00 CST 2013, time=2013-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038450, encodeId=2e9c203845040, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Jun 14 04:07:00 CST 2013, time=2013-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655616, encodeId=a944165561622, content=<a href='/topic/show?id=93e12218000' target=_blank style='color:#2F92EE;'>#中心血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22180, encryptionId=93e12218000, topicName=中心血压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d7724759256, createdName=Homburg, createdTime=Thu Dec 13 20:07:00 CST 2012, time=2012-12-13, status=1, ipAttribution=)]
    2013-10-30 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=1837104, encodeId=8c08183e1048e, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Feb 25 01:07:00 CST 2013, time=2013-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725461, encodeId=69201e2546126, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Oct 30 23:07:00 CST 2013, time=2013-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038450, encodeId=2e9c203845040, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Jun 14 04:07:00 CST 2013, time=2013-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655616, encodeId=a944165561622, content=<a href='/topic/show?id=93e12218000' target=_blank style='color:#2F92EE;'>#中心血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22180, encryptionId=93e12218000, topicName=中心血压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d7724759256, createdName=Homburg, createdTime=Thu Dec 13 20:07:00 CST 2012, time=2012-12-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1837104, encodeId=8c08183e1048e, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Feb 25 01:07:00 CST 2013, time=2013-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725461, encodeId=69201e2546126, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Oct 30 23:07:00 CST 2013, time=2013-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038450, encodeId=2e9c203845040, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Jun 14 04:07:00 CST 2013, time=2013-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655616, encodeId=a944165561622, content=<a href='/topic/show?id=93e12218000' target=_blank style='color:#2F92EE;'>#中心血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22180, encryptionId=93e12218000, topicName=中心血压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d7724759256, createdName=Homburg, createdTime=Thu Dec 13 20:07:00 CST 2012, time=2012-12-13, status=1, ipAttribution=)]